Want to join the conversation?
$M 2Q15 PR: Sales totaled $6.104Bil, a decrease of 2.6% vs. $6.267Bil in 2Q14. Comparable sales on an owned plus licensed basis were down by 1.5%. Operating income totaled $436MM vs. $571MM in 2Q14. Net income was $217MM or $0.64 per diluted share vs. $292MM or $0.80 per diluted share in 2Q14.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.